Generative protein design market seen reaching $4.95 billion by 2030

The generative protein design market is projected to expand from $1.54 billion in 2025 to $4.95 billion by 2030 as AI, computational biology and biologics reshape drug discovery and protein engineering. North America leads now, while Asia-Pacific is expected to grow fastest as biotech and AI partnerships deepen.

Why it matters: - Generative protein design is moving from niche research into a broader commercial market tied to drug discovery, personalized medicine and industrial biotechnology. - The shift could speed up the creation of new proteins, antibodies and therapeutic molecules with more precise properties. - The market’s growth reflects rising demand for biologics and AI-enabled discovery tools across healthcare and life sciences.

What happened: - The Business Research Company projected the generative protein design market will grow from $1.54 billion in 2025 to $1.94 billion in 2026. - The report forecast the market will reach $4.95 billion by 2030. - The 2026 to 2030 period implies a 26.3% compound annual growth rate. - The report was published July 17, 2026. - The company also published a sample request page and the full market report.

The details: - The market’s recent growth has been driven by advances in structural biology, protein sequencing, computational biology and bioinformatics. - Increased pharmaceutical R&D spending on biologics and early machine learning models for molecular modeling also supported expansion. - Ongoing genome sequencing projects added to the momentum. - Generative protein design uses artificial intelligence, machine learning and computational modeling to engineer protein sequences with specific structures and biological functions. - Applications include drug discovery, healthcare, agriculture, biotechnology and industrial manufacturing. - The report identified AI-powered drug discovery platforms, synthetic biology, protein engineering, cloud-based computational infrastructure and biotech-AI partnerships as key growth drivers. - The report highlighted AI-enabled de novo protein design, generative model use in protein sequence optimization, large-scale cloud-based protein simulations and AI-driven enzyme engineering as major trends. - North America was the largest regional market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The regional analysis also covered South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The report points to a market that is becoming more practical and commercial as AI tools and computational power reduce the time and cost of designing proteins. - Growth in biologics matters because targeted therapies often depend on highly engineered proteins, which raises demand for specialized design platforms. - WHO said in February 2025 that the 2023 WHO Essential Medicines List included 81 biologic therapies, more than 15% of all listed medicines. - That biopharma shift helps explain why protein design is attracting more investment and attention.

What's next: - The market is expected to keep expanding as personalized medicine, targeted therapies and AI-based discovery workflows gain wider adoption. - More collaboration between biotechnology companies and AI providers is likely to shape the next phase of product development. - Cloud-based bioinformatics and computational biology platforms should become more central to large-scale protein design work.

The bottom line: - Generative protein design is emerging as a high-growth AI and biotech segment with a clear path to multibillion-dollar scale by 2030.